148 related articles for article (PubMed ID: 33758148)
1. Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities.
Zhang D; Tailor TD; Kim C; Atkins MB; Braithwaite D; Akinyemiju T
J Immunother; 2021 Jun; 44(5):198-203. PubMed ID: 33758148
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
3. Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB).
Gupta A; Zhang D; Braithwaite D; Karanth SD; Tailor TD; Clarke JM; Akinyemiju T
J Immunother; 2022 Feb-Mar 01; 45(2):132-137. PubMed ID: 34747372
[TBL] [Abstract][Full Text] [Related]
4. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and stage at diagnosis among lung cancer patients in the US military health system.
Lin J; McGlynn KA; Nations JA; Shriver CD; Zhu K
Cancer Causes Control; 2020 Mar; 31(3):255-261. PubMed ID: 31984449
[TBL] [Abstract][Full Text] [Related]
6. Utilization pattern and service settings of palliative care for patients with metastatic non-small cell lung cancer.
Huo J; Hong YR; Turner K; Bian J; Grewal R; Wilkie DJ
Cancer; 2019 Dec; 125(24):4481-4489. PubMed ID: 31449674
[TBL] [Abstract][Full Text] [Related]
7. Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
Schroeder MC; Tien YY; Wright K; Halfdanarson TR; Abu-Hejleh T; Brooks JM
Lung Cancer; 2016 May; 95():28-34. PubMed ID: 27040848
[TBL] [Abstract][Full Text] [Related]
8. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
9. Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.
Ahn DH; Mehta N; Yorio JT; Xie Y; Yan J; Gerber DE
Clin Lung Cancer; 2013 Nov; 14(6):644-50. PubMed ID: 23886797
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database.
Gupta A; Omeogu C; Islam JY; Joshi A; Zhang D; Braithwaite D; Karanth SD; Tailor TD; Clarke JM; Akinyemiju T
Sci Rep; 2023 May; 13(1):8190. PubMed ID: 37210410
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Bailey H; Lee A; Eccles L; Yuan Y; Burlison H; Forshaw C; Varol N
BMC Cancer; 2023 Jun; 23(1):603. PubMed ID: 37386452
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care of nonsmall cell lung cancer patients in China and implications for survival.
He Y; Yu XQ; Luo Q; Xu X; Wang Y; Li S; Shan B
J Cancer Res Ther; 2018 Jun; 14(Supplement):S410-S415. PubMed ID: 29970698
[TBL] [Abstract][Full Text] [Related]
13. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study.
Nilsson J; Berglund A; Bergström S; Bergqvist M; Lambe M
Acta Oncol; 2017 Jul; 56(7):949-956. PubMed ID: 28486004
[TBL] [Abstract][Full Text] [Related]
14. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.
Wang S; Wong ML; Hamilton N; Davoren JB; Jahan TM; Walter LC
J Clin Oncol; 2012 May; 30(13):1447-55. PubMed ID: 22454424
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
Kocher F; Hilbe W; Seeber A; Pircher A; Schmid T; Greil R; Auberger J; Nevinny-Stickel M; Sterlacci W; Tzankov A; Jamnig H; Kohler K; Zabernigg A; Frötscher J; Oberaigner W; Fiegl M
Lung Cancer; 2015 Feb; 87(2):193-200. PubMed ID: 25564398
[TBL] [Abstract][Full Text] [Related]
17. Differences in initial treatment patterns and outcomes of lung cancer in the elderly.
Smith TJ; Penberthy L; Desch CE; Whittemore M; Newschaffer C; Hillner BE; McClish D; Retchin SM
Lung Cancer; 1995 Dec; 13(3):235-52. PubMed ID: 8719064
[TBL] [Abstract][Full Text] [Related]
18. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis.
Tung A; Hepp Z; Bansal A; Devine EB
J Manag Care Spec Pharm; 2017 Apr; 23(4):474-482. PubMed ID: 28345436
[TBL] [Abstract][Full Text] [Related]
19. Association Between Treatment Facility Volume, Therapy Types, and Overall Survival in Patients With Stage IIIA Non-Small Cell Lung Cancer.
Kommalapati A; Tella SH; Appiah AK; Smith L; Ganti AK
J Natl Compr Canc Netw; 2019 Mar; 17(3):229-236. PubMed ID: 30865920
[TBL] [Abstract][Full Text] [Related]
20. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA
Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
